MediciNova enrolls first patient in NIH-funded trial for ALS drug MN-166

From GlobeNewswire: 2025-04-08 19:00:00

MediciNova, Inc. has enrolled the first patient in the NIH-funded Expanded Access Program (EAP) trial for MN-166 (ibudilast) in ALS patients, offering access to 200 individuals. The trial aims to evaluate the safety and efficacy of MN-166 in advanced ALS stages. MN-166 is a compound in late-stage development for ALS, progressive MS, DCM, glioblastoma, Long COVID, CIPN, and substance use disorder. It holds Orphan Drug Designation and Fast Track Designation by the FDA for ALS treatment. MediciNova expresses gratitude to the NIH and NINDS for their support. MN-166 is the lead asset in MediciNova’s pipeline for neurodegenerative diseases.



Read more at GlobeNewswire: First Patient Enrolled in NIH-Funded Expanded Access